Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.60 Average PT from Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX) has earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $6.60.

A number of research firms have issued reports on CNTX. Lifesci Capital upgraded Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research note on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. Wall Street Zen cut shares of Context Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Finally, Piper Sandler lifted their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th.

Institutional Investors Weigh In On Context Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CNTX. Octagon Capital Advisors LP bought a new stake in shares of Context Therapeutics during the first quarter valued at about $13,755,000. Millennium Management LLC bought a new stake in shares of Context Therapeutics during the fourth quarter valued at about $3,824,000. Marshall Wace LLP raised its stake in shares of Context Therapeutics by 7,153.7% during the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after purchasing an additional 2,557,448 shares in the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Context Therapeutics during the first quarter valued at about $500,000. Finally, Renaissance Technologies LLC raised its stake in shares of Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after purchasing an additional 188,202 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Stock Performance

CNTX stock opened at $0.68 on Thursday. The stock has a market capitalization of $62.40 million, a price-to-earnings ratio of -1.62 and a beta of 1.61. Context Therapeutics has a 1 year low of $0.56 and a 1 year high of $3.62. The stock’s fifty day moving average is $2.30 and its two-hundred day moving average is $2.10.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. As a group, analysts predict that Context Therapeutics will post -0.35 EPS for the current fiscal year.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.